T1	Participants 46 77	chronic schizophrenic patients:
T2	Participants 248 284	40 chronic schizophrenic in-patients
T3	Participants 170 230	cyproheptadine augmentation of ongoing haloperidol treatment
T4	Participants 914 1026	chronic schizophrenic patients who are intolerant of extrapyramidal side effects of conventional antipsychotics.
T5	Participants 514 537	extrapyramidal symptoms
